- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01062191
Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl (ROM)
Flexible Hydrogel Nanoparticle Wound Dressing Allows Greater Joint Range of Motion Compared to Typical Sodium Carboxymethylcellulose Dressing
Study Overview
Status
Conditions
Detailed Description
This is a single center, randomized, single blind therapeutic exploratory study to monitor the range of motion of wounds treated with the new nanoparticle hydrogel dressing compared to the range of motion of wounds treated with existing treatment standard (sodium carboxymethylcellulose dressing) in patients with partial thickness burns. A total of 50 joints will be studied. The patients will be at least 7 years of age.. The Department of Physical Medicine and Rehabilitation at Parkland Hospital and Health System, UT Southwestern, will be asked to enroll enough patients to meet the proposed 50 joint study sites (approximately 3-5 afflicted joints per patient). Children will be included in the patient population if possible. Inclusion criteria for the medical condition will be at least one partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints. As a control, the patients will also need to have an unburned contralateral joint without major internal or external joint derangement.
The Primary Investigator will first identify the study site and control site for each patient and take the initial measurements. Trained personnel will apply the bandage to the study site. No secondary bandage will be applied. Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study. Both the patient and medical staff will be trained on patient use instructions for the dressing. The patients will be monitored for a short time after application of the bandage as part of standard procedure, and the patient is then allowed to go home with instructions for care. Within 2-8 days after application, the dressing will be inspected and range of motion will be measured for both the study site and the control site. Any concomitant treatment (medications, wound care) will be thoroughly documented for the duration of the study. Both dressings are designed to remain on the wound until the bandage falls off, which indicates re-epithelialization of the wound. The dressings should not be removed by the patient or medical staff unless there are signs of infection, deterioration of bandage, or other adverse event. If the bandage falls off, the patient is instructed to immediately call the medical staff.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patient is at least 2 years of age;
- Patient is in general good health;
- Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints;
- Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control
- Patient is willing and able to cooperate with the protocol for 30 days
- Patient is capable of provided informed consent
- Patient provides authorization for use and disclosure of protected health information
Exclusion Criteria:
- Age less than 2 years;
- Patient has superficial or full thickness burn wounds;
- Patient has acutely infected wounds;
- Patient has wounds with surrounding cellulites;
- Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments
- Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;
- Patient is wearing any type of orthopedic device that may come in contact with the dressing;
- Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination
- Patient has wound originating from chronic condition
- Patients with history of any immunodeficiency syndrome or condition
- Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? )
- Patient has participated in a clinical research study within the last 30 days prior to enrollment;
- Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Nanoflex Powder Dressing applied to joint
|
Wound dressing
|
|
Active Comparator: Aquacel AG, typical carboxymethylcellulose dressing
Sodium CMC dressing control applied to joint
|
4" X 4", Aquacel silver sheet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Range of motion in burned joints with dressing in place as compared to control
Time Frame: Up to 2 weeks
|
Up to 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pain at joint with dressing in place
Time Frame: up to 2 weeks
|
up to 2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- U-C-6U1101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn
-
Dr Muhammad Naveed ShahzadNot yet recruitingSilver Sulfadiazine With Hyaluronic Acid Versus Silver Sulfadiazine Alone in Partial-Thickness BurnsPartial-Thickness Burn, Thermal BurnPakistan
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
The First Affiliated Hospital of Xinxiang Medical...Not yet recruitingBurn | Burn Degree Second | Burn Contracture of Skin
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.RecruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
Integra LifeSciences CorporationWithdrawnBurn Scar | Burn Injury | Skin Grafting | Burn Wounds - Partial Thickness (2nd Degree)
-
University Hospital Schleswig-HolsteinUniversity of LuebeckRecruitingSecond-degree Burn | Third-Degree BurnGermany
-
General Electric ResearchTerminatedBurn Wound | 2nd Degree Burn of the SkinUnited States
-
University Hospital, LinkoepingCompletedBurn Scar | Burns | Burn Second DegreeSweden
-
S.K. Lerik General HospitalCompletedBurn Scar | Burns | Burn Degree Second | Electrical BurnIndonesia
Clinical Trials on Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
-
Taipei Veterans General Hospital, TaiwanCompletedWounds and Injuries | Surgical Wound | Cesarean Section | Surgical Wound InfectionTaiwan
-
Lavior Pharma Inc.CompletedDiabetic Foot UlcerUnited States
-
University Hospital, CaenSociété de Dermatologie FrançaiseCompleted
-
ULURU Inc.United States Department of DefenseRecruitingPressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
ULURU Inc.Naval Medical Research Center; Military Technology Enterprise Consortium (US)CompletedDiabetic Foot UlcerUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States